SIFI Fusioniert mit Faes Farma und Stärkt Ophthalmologie-Präsenz
Deal News | Jun 10, 2025 | PR Newswire Cision SIFI S.p.A.
SIFI, a leading ophthalmology company based in Italy, is set to be acquired by Faes Farma, a prominent European pharmaceutical firm, following a unanimous shareholder agreement. The acquisition, subject to conditions, promises robust commercial synergies through Faes Farma’s existing market presence and its recent acquisition of Laboratorios Edol. With this merger, SIFI will benefit from Faes Farma's complementary geographic reach, which aids in positioning ophthalmology as a key area—accounting for about 20% of the combined Group's pro forma revenue. This integration will enhance SIFI's production facilities in Aci S. Antonio, Sicily. Additionally, the transaction facilitates ongoing development of Akantior, a treatment for Acanthamoeba Keratitis, and other innovative projects, particularly in the U.S., expanding access to SIFI's pipeline. The transaction entails a valuation at a double-digit EBITDA multiple, expecting completion by Q3 2025, contingent on regulatory approvals. The deal is supported by strategic advisors such as Evercore and Mediobanca.
Sectors
- Pharmaceuticals
- Healthcare
Geography
- Italy – SIFI is based in Italy, and its facilities in Aci S. Antonio will remain central to operations post-merger.
- Spain – Faes Farma, a Spanish pharmaceutical company, is the acquiring firm in this transaction.
- Europe – The transaction impacts multiple European markets including Italy, France, and Iberian regions, aiming for market expansion in the region.
- United States – Focus on further development of SIFI's Akantior product in the U.S. is a key strategic element of the merger.
Industry
- Pharmaceuticals – The article discusses a transaction between SIFI, an ophthalmology company, and Faes Farma, a pharmaceutical giant, highlighting their involvement in the health sector, and the development of innovative therapies.
- Healthcare – A focus on ophthalmology and treatment developments such as Akantior for rare conditions emphasizes the relevance of the healthcare industry in the transaction.
Financials
- Double-digit EBITDA multiple – The transaction values SIFI based on a double-digit multiple of its 2024 EBITDA.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| SIFI S.p.A. | Target Company | Company | An Italian ophthalmology firm with expertise in pharmaceuticals and medical devices, undergoing acquisition by Faes Farma. |
| Faes Farma | Buying Company | Company | A Spanish pharmaceutical giant listed on the Spanish stock exchange, acquiring SIFI to expand its portfolio and market presence in ophthalmology. |
| Evercore Partners International LLP | Financial Advisor | Company | Acts as exclusive financial advisor to SIFI's shareholders regarding the transaction. |
| Mediobanca - Banca di Credito Finanziario S.p.A. | Financial Advisor | Company | Also acts as an exclusive financial advisor for SIFI's shareholders. |
| J.P. Morgan SE | Financial Advisor and Debt Provider | Company | Serves as financial advisor and debt provider for Faes Farma in the transaction. |
| Hogan Lovells Studio Legale | Legal Advisor | Company | Acts as legal advisor for SIFI in the transaction. |
| Cuatrecasas Legal SLP | Legal Advisor | Company | Provides legal advisory services to Faes Farma for the transaction. |